Imuran (Azathioprine)

Azathioprine is a purine analog that is metabolized inside cells to 6‑mercaptopurine. This metabolite blocks the synthesis of new purine nucleotides, which are essential for DNA replication. By limiting DNA synthesis, the drug reduces the proliferation of activated T‑ and B‑lymphocytes, thereby decreasing immune activity and inflammation.

The dosage of Imuran is individualized. A qualified prescriber determines the appropriate dose based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Patients should follow the prescribing clinician’s instructions and not adjust the dose on their own.

The safety of azathioprine in pregnancy and lactation is not fully established. It should only be used when the potential benefits to the mother outweigh possible risks to the fetus or infant, and this decision must be made by a specialist. Breastfeeding mothers should discuss risks with their healthcare provider.

To order Imuran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Azathioprine belongs to the antimetabolite class of immunosuppressants, differing from calcineurin inhibitors like cyclosporine or tacrolimus, which act on T‑cell activation pathways. Azathioprine’s oral administration and long‑term safety profile make it suitable for many chronic autoimmune conditions, whereas calcineurin inhibitors are often preferred for rapid, potent suppression in transplant protocols.

Imuran tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light, and store them out of reach of children. Do not refrigerate or freeze the tablets.

Imuran is taken orally as a tablet, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule—once daily or divided doses—depends on the prescriber’s instructions and the condition being treated.

Serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity, pancreatitis, opportunistic infections, and an increased long‑term risk of certain malignancies such as lymphoma or skin cancer. Patients should undergo regular blood monitoring to detect early signs of these complications.

Imuran is contraindicated in patients with known hypersensitivity to azathioprine or its metabolites, those with severe hepatic impairment, and individuals who are pregnant or breastfeeding unless the benefits clearly outweigh the risks. It should also be avoided in patients with active, uncontrolled infections.